Company Stemline Therapeutics, Inc.
Equities
US85858C1071
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ivan Bergstein
CEO | Chief Executive Officer | 58 | 07/08/03 |
David Gionco
DFI | Director of Finance/CFO | 63 | 15/01/14 |
Jeffrey Levitt
CMP | Compliance Officer | - | 28/02/18 |
Nassir Habboubi
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/20 |
Kenneth Hoberman
COO | Chief Operating Officer | 59 | 31/12/12 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ivan Bergstein
CEO | Chief Executive Officer | 58 | 07/08/03 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 52,510,785 | 52,125,679 ( 99.27 %) | 0 | 99.27 % |
Company contact information
Stemline Therapeutics, Inc.
750 Lexington Avenue 11th floor
10022, New York
+646-502-2310
http://www.stemline.comSector
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |